CWP
CRSP icon

Cyndeo Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

Cyndeo Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Buy
6,978
+1,255
+22% +$66.1K 0.02% 394
2026
Q1 		$272K Buy
5,723
+93
+2% +$4.91K 0.01% 425
2025
Q4 		$295K Buy
5,630
+1,640
+41% +$98.2K 0.02% 405
2025
Q3 		$259K Buy
+3,990
New +$229K 0.01% 419
2024
Q2 		– Sell
-5,275
Closed -$360K – 399
2024
Q1 		$360K Buy
5,275
+30
+0.6% +$2.15K 0.03% 304
2023
Q4 		$328K Buy
+5,245
New +$290K 0.03% 298

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cyndeo Wealth Partners's CRSP Position: Q2 2026 in Review

Cyndeo Wealth Partners increased its CRISPR Therapeutics (CRSP) stake by 22% in Q2 2026, buying an estimated $66.1K and bringing the position to 6,978 shares worth $381K. The position accounts for 0.02% of the portfolio, ranked #394.

Cyndeo Wealth Partners first reported a position in CRSP in Q4 2023 and has held it in 6 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Cyndeo Wealth Partners held 6,978 shares of CRISPR Therapeutics worth $381K as of Q2 2026.
  • Cyndeo Wealth Partners bought 1,255 CRISPR Therapeutics shares in Q2 2026, an estimated $66.1K.
  • CRISPR Therapeutics made up 0.02% of Cyndeo Wealth Partners's portfolio in Q2 2026, its #394 holding.
  • Cyndeo Wealth Partners first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Cyndeo Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.